An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Exclusion Criteria

• •Have radiographic sacroiliitis fulfilling the 1984 modified New York Criteria
• •Have other inflammatory diseases that might confound the evaluations of benefit from the ustekinumab therapy
• •Have received any systemic immunosuppressives or disease-modifying anti-rheumatic drug (DMARDs) other than methotrexate (MTX), sulfasalazine (SSZ), or hydroxychloroquine (HCQ) within 4 weeks prior to first administration of study agent
• •Have received epidural, intra-articular, intramuscular (IM), or intravenous (IV) corticosteroids, including adrenocorticotropic hormone during the 4 weeks prior to first administration of study agent
• •Have received prior biologic therapy other than anti-TNFα
• •Have received more than 1 prior anti-TNFα agent